Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, Ma G, Wang X, Gan S, Sun J, Jin P, Yi J, Shi B, Ma J, Ye S, Wang G, Ji L, Gu X, Yu T, An P, Deng H, Li H, Li L, Ma Q, Qian L, Yang W. Zhang B, et al. Among authors: cheng z. Diabetes Care. 2024 Jan 1;47(1):160-168. doi: 10.2337/dc23-1287. Diabetes Care. 2024. PMID: 37943529 Free PMC article. Clinical Trial.
Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study.
Zhang X, Ran X, Xu Z, Cheng Z, Shen F, Yu Y, Gao L, Chai S, Wang C, Liu J, Liu J, Sun Z, Zhao J, Ji L; China DIA-LEAD Study Investigators. Zhang X, et al. Among authors: cheng z. J Diabetes Complications. 2018 Feb;32(2):150-156. doi: 10.1016/j.jdiacomp.2017.10.003. Epub 2017 Oct 13. J Diabetes Complications. 2018. PMID: 29191431
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J. Weng J, et al. Among authors: cheng z. Diabetes Obes Metab. 2021 Aug;23(8):1754-1764. doi: 10.1111/dom.14389. Epub 2021 Apr 14. Diabetes Obes Metab. 2021. PMID: 33769656 Clinical Trial.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E; LixiLan-O-AP trial investigators. Yang W, et al. Among authors: cheng z. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. Diabetes Obes Metab. 2022. PMID: 35441412 Clinical Trial.
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L, Cheng Z, Su B, Su X, Song W, Guo Y, Liao L, Chen X, Li J, Tan X, Xu F, Pang S, Wang K, Ye J, Wang Y, Chen L, Sun J, Ji L. Gao L, et al. Among authors: cheng z. Diabetes Obes Metab. 2023 Mar;25(3):785-795. doi: 10.1111/dom.14926. Epub 2022 Dec 12. Diabetes Obes Metab. 2023. PMID: 36433709 Clinical Trial.
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
Ji L, Jiang X, Hao Q, Cheng Z, Wang K, Pang S, Liu M, Guo Y, Chen X, Su X, Ning T, Liu J, Bian F, Li Y, Zhang Z, Song W, Sun J. Ji L, et al. Among authors: cheng z. Diabetes Obes Metab. 2023 May;25(5):1229-1240. doi: 10.1111/dom.14971. Epub 2023 Jan 20. Diabetes Obes Metab. 2023. PMID: 36594724 Clinical Trial.
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
Ji L, Lu J, Gao L, Yan X, Li J, Cheng Z, Zhang L, Tian J, Li P, Bai J, Xie D, Zhao J, Ding J, Yu Q, Wang T. Ji L, et al. Among authors: cheng z. Diabetes Obes Metab. 2023 Dec;25(12):3788-3797. doi: 10.1111/dom.15274. Epub 2023 Sep 19. Diabetes Obes Metab. 2023. PMID: 37724698 Clinical Trial.
Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
Wang W, Yan X, Cheng Z, Zhang Q, Wang R, Deng Y, Ma J, Zhu D. Wang W, et al. Among authors: cheng z. Diabetes Obes Metab. 2023 Dec;25(12):3690-3699. doi: 10.1111/dom.15263. Epub 2023 Sep 21. Diabetes Obes Metab. 2023. PMID: 37732487 Clinical Trial.
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Li Y, Cheng Z, Lu W, Li P, Jiang H, Yang J, Xu J, Zhang C, Zhang L, Wang Y, Bian F, Guo W, Yu X, Chen X, Zhao D, Feng B, Qu S, Qin J, Zhang Y, Wang L, Cheng H, Mu Y. Li Y, et al. Among authors: cheng z, cheng h. Diabetes Obes Metab. 2024 Mar;26(3):1057-1068. doi: 10.1111/dom.15407. Epub 2023 Dec 17. Diabetes Obes Metab. 2024. PMID: 38105342 Clinical Trial.
9,427 results